Gen House Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2014

Location

Suzhou Zhejiang China

Primary Industry

Pharmaceuticals

About

Established in 2014 and based in Suzhou, China, Gen House operates as a biotechnology company focusing on the development of small molecule antitumor new drugs. Kuifeng Wang, the company's founder and CEO, graduated from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and is also a candidate for the National Major Talent Project. It has a branch office in Shanghai. The company cooperated with Zhejiang University, Wuxi AppTec, Shanghai Institute of Material Medica, Chinese Academy of Sciences. In 2020, the company reached a cooperation with Huya International to realize commercialization in the early stage of drug development. Gen House mainly engages in the research and development of small molecule antitumor new drugs. The company has established a structural biology research platform, an early drug screening platform, and a preclinical evaluation platform, forming a product pipeline with targeted antitumor products as the core. Its main products include GH35, GH21, GH55 and GH52, etc. GH21 is a small molecule SHP2 inhibitor. The company generates revenue by providing small molecule antitumor new drugs.

Current Investors

Sharewin Investment, Dynamic Capital, Topping Capital

Request a demo to show more

Primary Industry

Pharmaceuticals

Sub Industries

Biopharmaceuticals, Pharmaceutical Research & Development

Website

www.genhousebio.com

Verticals

HealthTech

Company Stage

Series B

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.